Agree Realty
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Agree Realty Corporation functions as a publicly traded Real Estate Investment Trust (REIT), concentrating its efforts on the acquisition and development of commercial properties. These assets are pri...
Latest News
18 hours ago · seekingalpha.com
Mr. Market Just Gave Me A Huge Gift For De-Risking My PortfolioThe market, despite not being cheap right now, just did me a huge favor as I prepare my portfolio for the biggest risk facing my investments in the coming years. I discuss the risks I am most concerned about and how they could impact investor portfolios. I also detail how I am preparing my portfolio to weather this potential storm.
4 days ago · globenewswire.com
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload PlatformInitiated GLP toxicology studies of lead TROP2-targeted ADC AKTX-101 to enable planned Phase 1 trial in mid-2027 New preclinical findings demonstrate anti-tumor activity in urothelial cancer models resistant to currently approved ADC therapies, reinforcing the potential of novel PH1 payload for patients relapsing on current ADC therapies Collaboration with Whitehawk Therapeutics on novel dual payloads emphasizes PH1 payload's strategic partnering opportunities Strengthened balance sheet with approximately $3 million in proceeds from warrant exercises, ending the quarter with $5.7 million in cash TAMPA, Fla. and LONDON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today reported financial results for the third quarter ended September 30, 2026, and highlighted significant progress advancing its proprietary PH1 payload platform toward Phase 1 clinical development.
4 days ago · seekingalpha.com
Realty Income Delivers 18% Alpha Over Agree RealtyWe had previously written two comparative articles on the merits of investing in Realty Income or Agree Realty. We picked a clear favorite, and it worked out over the last 2 years. We review the situation today and tell you why we are upgrading one.
8 days ago · 247wallst.com
3 Monthly Dividend Stocks That Could Help Pay Your Retirement BillsYour bills show up every month, but most dividend checks only arrive four times a year. Three monthly payers promise to close that gap, though one of them carries a hidden catch that could shrink part of the paycheck.
8 days ago · prnewswire.com
ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational UpdatesThird quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026 Strategic financial restructuring strengthens balance sheet, extending expected cash runway into 2029 Abstracts accepted for presentation at ASH 2026, highlighting ZYNLONTA's potential across multiple B-cell malignancies Tanabe's marketing authorization application filing and sublicensing in Japan support anticipated regulatory and commercial milestones for ADC Therapeutics LAUSANNE, Switzerland, Nov. 9, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported full financial results for the third quarter ended September 30, 2026, and provided recent operational updates. "During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
12 days ago · marketbeat.com
ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III StudyADC Therapeutics NYSE: ADCT outlined new lymphoma data and plans for further studies of its cancer drug ZYNLONTA, while reporting preliminary third-quarter sales of approximately $21 million and an expected cash runway into 2029.
12 days ago · 247wallst.com
4 Monthly Dividend Stocks That Could Pay You Like Clockwork in RetirementMost dividend stocks pay quarterly, leaving retirees to juggle bills against an awkward schedule.
13 days ago · seekingalpha.com
Hard To Imagine A Retirement Portfolio Without These 2 Dividend MachinesRetiring on dividends comes down to two things: income you can count on and returns that make saving easier. Since those two goals pull against each other, I use a specific payout and cash-flow test to find the right balance. That test leaves out many popular dividend names but highlights two businesses built for decades of steady income.
13 days ago · prnewswire.com
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical ProgramZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy-evaluable r/r DLBCL patients Phase 2 marginal zone lymphoma IIT abstract shows robust and durable 93% ORR and 74.4% CRR with ZYNLONTA monotherapy Company to host conference call today at 4:15 p.m. EST LAUSANNE, Switzerland, Nov. 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced new and updated data from the ZYNLONTA® (loncastuximab tesirine-lpyl) clinical program will be shared across multiple abstracts, including five oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting taking place December 12–15, 2026, in New Orleans, Louisiana.
14 days ago · 247wallst.com
Realty Income Just Raised Its Dividend Again. Here Are 2 More Monthly PayersMost dividend stocks make you wait three months between payments, but a small group of NYSE companies cut those checks every single month and keep raising the amount. Three of them clear every safety bar worth checking.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ADC